Literature DB >> 3595706

Effects of josamycin on carbamazepine kinetics.

G Vinçon, H Albin, F Demotes-Mainard, M Guyot, C Bistue, P Loiseau.   

Abstract

The steady state pharmacokinetics of oral carbamazepine in epileptic patients (n = 8) was compared before and after one week of treatment with josamycin (2 g/day). There was a small but statistically significant decrease in oral clearance of total (17%) and unbound (21.5%) drug. In spite of an unchanged AUC of 10,11-epoxide carbamazepine the ratio of metabolite to parent drug AUC was significantly decreased (20.2%). The plasma protein binding of carbamazepine and its 10,11-epoxide metabolite did not vary. The results demonstrate impairment by josamycin of the apparent clearance of carbamazepine. Care should be taken in patient receiving both carbamazepine and josamycin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3595706     DOI: 10.1007/bf00607583

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  [Is triacetyl oleandomycin-ergotamine tartrate combination dangerous?].

Authors:  B Bigorie; P Aimez; R J Soria; F Samama; G di Maria; B Guy-Grand; H Bour
Journal:  Nouv Presse Med       Date:  1975-11-08

2.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

3.  Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics.

Authors:  L K Webster; G W Mihaly; D B Jones; R A Smallwood; J A Phillips; F J Vajda
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  [Influence of josamycine treatment on carbamazepine kinetics (author's transl)].

Authors:  H Albin; G Vinçon; F Pehourcq; J Dangoumau
Journal:  Therapie       Date:  1982 Mar-Apr       Impact factor: 2.070

5.  Plasma protein binding of carbamazepine.

Authors:  W D Hooper; D K Dubetz; F Bochner; L M Cotter; G A Smith; M J Eadie; J H Tyrer
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

6.  Carbamazepine metabolism in man. Induction and pharmacogenetic aspects.

Authors:  M Eichelbaum; T Tomson; G Tybring; L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

7.  Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva.

Authors:  H G Westenberg; E van der Kleijn; T T Oei; R A de Zeeuw
Journal:  Clin Pharmacol Ther       Date:  1978-03       Impact factor: 6.875

8.  Carbamazepine and its 10,11-epoxide in children and adults with epilepsy.

Authors:  S Pynnönen; M Sillanpää; H Frey; E Iisalo
Journal:  Eur J Clin Pharmacol       Date:  1977-01-03       Impact factor: 2.953

9.  Carbamazepine intoxication due to triacetyloleandomycin administration in epileptic patients.

Authors:  E Mesdjian; C Dravet; B Cenraud; J Roger
Journal:  Epilepsia       Date:  1980-10       Impact factor: 5.864

10.  Effects of erythromycin on hepatic drug-metabolizing enzymes in humans.

Authors:  D Larrey; C Funck-Brentano; P Breil; J Vitaux; C Theodore; G Babany; D Pessayre
Journal:  Biochem Pharmacol       Date:  1983-03-15       Impact factor: 5.858

View more
  9 in total

Review 1.  Formulary management of macrolide antibiotics.

Authors:  D R Guay
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

Review 2.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

Review 3.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

4.  Interactions Between Antiepileptic and Antibiotic Drugs: A Systematic Review and Meta-Analysis with Dosing Implications.

Authors:  Carla Carnovale; Marco Pozzi; Faizan Mazhar; Giulia Mosini; Marta Gentili; Gabriëlla G A M Peeters; Emilio Clementi; Sonia Radice
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

Review 5.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 6.  Macrolide antibacterials. Drug interactions of clinical significance.

Authors:  N A von Rosensteil; D Adam
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

Review 7.  Pharmacokinetic drug interactions of macrolides.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

Review 8.  Pharmacokinetic drug interactions with antimicrobial agents.

Authors:  J G Gillum; D S Israel; R E Polk
Journal:  Clin Pharmacokinet       Date:  1993-12       Impact factor: 6.447

Review 9.  Antiepileptic drugs. A review of clinically significant drug interactions.

Authors:  P N Patsalos; J S Duncan
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.